Aspirin Dose and Atherosclerosis in Patients With Heart Disease
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 40 - 80 |
| Updated: | 12/30/2018 |
| Start Date: | October 2006 |
| End Date: | June 2009 |
A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)
The purpose of the study is to test higher versus lower doses of aspirin on markers of
atherosclerosis in patients who have had a heart attack.
atherosclerosis in patients who have had a heart attack.
Aspirin reduces risks of heart attacks, strokes, and deaths from cardiovascular causes in
patients who have survived a prior event as well as during an acute heart attack.
Low dose aspirin is sufficient to achieve complete inhibition of platelet aggregability, or
stickiness, and this is the mechanism whereby aspirin prevents formation of blood clots.
Our research is designed to explore whether higher doses of aspirin provide additional
benefits on markers of atherosclerosis.
patients who have survived a prior event as well as during an acute heart attack.
Low dose aspirin is sufficient to achieve complete inhibition of platelet aggregability, or
stickiness, and this is the mechanism whereby aspirin prevents formation of blood clots.
Our research is designed to explore whether higher doses of aspirin provide additional
benefits on markers of atherosclerosis.
Inclusion Criteria:
1. Age 40 to 80 years, inclusive.
2. Patients with stable coronary disease, with and without diabetes mellitus, defined by:
1. angiographic evidence of 70% or greater stenosis, or
2. previous percutaneous coronary intervention (PCI), or
3. coronary artery bypass graft (CABG), or
4. history of a MI, or
5. positive exercise test
Exclusion Criteria:
1. Patients taking greater than 81mg aspirin daily.
2. Patients taking any of the following medications for less than 3 months, or who plan
to take them for the first time during the next 3 months: ACE-inhibitors, angiotensin
receptor blockers, calcium channel blockers, or statins.
3. Patients within 6 months of a coronary intervention, including PCI or CABG.
4. Patients with a planned coronary intervention.
5. Patients taking anti-platelet drugs such as clopidogrel or non-steroidal
anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin.
6. Patients who are currently cigarette smokers.
7. Women patients who are pregnant, planning to become pregnant, nursing a child, or
taking hormone replacement therapy.
8. Patients with any coagulation, bleeding or blood disorders.
9. Patients who are sensitive or allergic to aspirin.
10. Patients with documented history of any gastrointestinal disorders, including bleeding
ulcers.
11. Patients with any evidence of cancer or kidney, liver, lung, blood, or brain
disorders.
12. Patients with asthma, rhinitis, or nasal polyps.
13. Patients with any abnormal laboratory value or physical finding that, in the view of
the responsible clinician, may interfere with interpretation of the trial results, be
indicative of an underlying disease state, or compromise the safety.
14. Patients with Class IV heart failure.
15. Patients with severe aortic insufficiency, or aortic regurgitation.
16. Patients with hearing loss or tinnitus.
17. Patients with tremors which cause them not to be able to remain motionless for
approximately 30 seconds.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials